|
|
Volumn 3 Suppl 3, Issue , 2002, Pages
|
|
Recombinant human erythropoietin for neuroprotection: what is the evidence?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
NEUROPROTECTIVE AGENT;
RECOMBINANT ERYTHROPOIETIN;
ANIMAL;
BLOOD BRAIN BARRIER;
BRAIN INJURY;
CEREBROVASCULAR ACCIDENT;
CONTROLLED CLINICAL TRIAL;
CROSS-SECTIONAL STUDY;
DEMYELINATING DISEASE;
DISEASE MODEL;
EVIDENCE BASED MEDICINE;
FEMALE;
HUMAN;
INTRAMUSCULAR DRUG ADMINISTRATION;
INTRAPERITONEAL DRUG ADMINISTRATION;
MALE;
MOUSE;
PATHOLOGY;
RABBIT;
RAT;
REVIEW;
SENSITIVITY AND SPECIFICITY;
SPINAL CORD INJURY;
TREATMENT OUTCOME;
ANIMALS;
BLOOD-BRAIN BARRIER;
BRAIN INJURIES;
CEREBROVASCULAR ACCIDENT;
CONTROLLED CLINICAL TRIALS;
CROSS-SECTIONAL STUDIES;
DEMYELINATING DISEASES;
DISEASE MODELS, ANIMAL;
ERYTHROPOIETIN, RECOMBINANT;
EVIDENCE-BASED MEDICINE;
FEMALE;
HUMANS;
INJECTIONS, INTRAMUSCULAR;
INJECTIONS, INTRAPERITONEAL;
MALE;
MICE;
NEUROPROTECTIVE AGENTS;
RABBITS;
RATS;
SENSITIVITY AND SPECIFICITY;
SPINAL CORD INJURIES;
TREATMENT OUTCOME;
MLCS;
MLOWN;
|
|
EID: 0036982647
PISSN: 15268209
EISSN: None
Source Type: Journal
DOI: 10.3816/cbc.2002.s.021 Document Type: Review |
|
Times cited : (61)
|
|
References (36)
|
